Answers are grounded in this paper and cite their sources.
Clinical trial demonstrates durable responses and manageable toxicity with concurrent ibrutinib and CD19 CAR-T cells in relapsed chronic lymphocytic leukemia, indicating enhanced therapeutic efficacy.
Introduction: We previously reported that CD19-targeted chimeric antigen receptor-engineered T (CD19 CAR-T) cells could lead to durable responses in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) who had previously failed ibrutinib therapy. Since pre-clinical studies showed that ibrutinib might improve CAR-T cell anti-tumor efficacy and reduce cytokine release syndrome (CRS), we carried out a pilot study to evaluate the safety and efficacy of CD19 CAR-T cells with concurrent ibrutinib administration. Methods: We treated pts in a pilot cohort of a phase I/II trial (NCT01865617) to evaluate the concurrent administration of ibrutinib with infusion of a defined composition of 2x105 or 2x106/kg CD4+ and CD8+ CD19 CAR-T cells after lymphodepletion chemotherapy in pts with R/R CLL. Ibrutinib (420mg/day) was scheduled from at least 2 weeks before leukapheresis through at least 3 months (m) after CAR-T cell infusion. Results: Nineteen high risk CLL pts were included in this study. The median number of prior therapies was 5 (range: 1-10), and 17 pts (89%) had high risk cytogenetics (17p deletion and/or complex karyotype and/or 11q abnormalities). All pts had failed treatment with ibrutinib prior to study entry. Fourteen pts (74%) developed CRS (grade 1, n=6, 32%; grade 2, n=8, 42%). Despite robust expansion of CAR-T cells in blood (median peak: 159,157 transgene copies/μg DNA), we did not observe grade ≥ 3 CRS (Lee 2014 criteria). Five pts developed neurotoxicity (grade 3, n=5, 26%, CTCAE 4.03 criteria). Eighteen pts were evaluable for response at restaging 4 weeks after CAR-T cell infusion (one patient died from a presumed ibrutinib-induced cardiac arrhythmia during grade 2 CRS). Fifteen pts (83%) responded (CRi or PR) by iwCLL criteria (CRi, n=4, 22%; PR, n=11, 61%). Ten of 14 pts (71%) with nodal disease by CT achieved CR or PR by iwCLL CT criteria. We observed elimination of marrow disease by multi-parameter flow cytometry in 13 pts (72%) and 11 (61%) had no residual malignant clone by IGH sequencing. In responders by iwCLL criteria (n=15) the 1-year probabilities of OS and PFS were 80% (95% CI: 57-100) and 49% (95% CI: 23-100), respectively (median follow-up: 11m; Figure A-B). In pts who achieved MRD-negative marrow response by IGH sequencing (n=11), the 1-year probabilities of OS and PFS were 100% (95% CI: 12-100) and 62% (95% CI: 32-100), respectively (Figure C-D); 9 of 11 pts (82%) without MRD by IGH sequencing were free of disease at last follow-up (median follow-up: 9.5m). Bayesian comparisons showed the concurrent administration of ibrutinib was associated with higher probabilities of IGH-negative marrow response and lower probabilities of grade ≥ 3 CRS, compared to pts treated with CD19 CAR-T cells alone. Keywords: chronic lymphocytic leukemia (CLL); ibrutinib; immune system. Disclosures: Lymp, J: Employment Leadership Position: Juno Therapeutics, A Celgene Company; Stock Ownership: Juno Therapeutics, A Celgene Company. Li, D: Employment Leadership Position: Juno Therapeutics, A Celgene Company; Stock Ownership: Juno Therapeutics, A Celgene Company. Riddell, S: Consultant Advisory Role: Cell Medica, Adaptive Biotechnologies, NOHLA; Research Funding: Juno Therapeutics. Maloney, D: Honoraria: Janssen Scientific Affairs, Seattle Genetics, Roche/Genentech; Research Funding: Juno Therapeutics, GlaxoSmithKline. Turtle, C: Consultant Advisory Role: Juno Therapeutics, Nektar Therapeutics, Eureka Therapeutics, Precision Biosciences, Caribou Biosciences.
No takes yet. Share an insight, caveat, or question.
Gauthier et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: